Bupivacaine 29.3 mg/ML / meloxicam 0.88 mg/ML Injection [Zynrelef]
RxNorm 2560314

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2560314 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: bupivacaine 29.3 mg/ML / meloxicam 0.88 mg/ML Injection [Zynrelef].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBD
Bupivacaine 29.3 mg/ML / meloxicam 0.88 mg/ML Injection [Zynrelef]
AUI:12650841
View
TMSY
BUPivacaine 29.3 mg/ML / meloxicam 0.88 mg/ML Injection [Zynrelef]
AUI:12815470
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBD

Semantic Branded Drug (SBD):
Bupivacaine 29.3 mg/ML / meloxicam 0.88 mg/ML Injection [Zynrelef]
(Atom ID: 12650841)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
bupivacaine 29.3 MG/ML / meloxicam 0.88 MG/ML Injection [Zynrelef]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
E
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2560314
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12650841
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
2560314
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
TMSY

Tall Man Lettering Synonym (TMSY):
BUPivacaine 29.3 mg/ML / meloxicam 0.88 mg/ML Injection [Zynrelef]
(Atom ID: 12815470)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
BUPivacaine 29.3 MG/ML / meloxicam 0.88 MG/ML Injection [Zynrelef]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
E
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2560314
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12815470
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
2560314
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.